Adopting intensive lifestyle changes can slow or stop progression of early-stage Alzheimer’s disease, according to a new ...

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

People who follow a MIND diet, even if started later in life, were significantly less likely to develop Alzheimer's disease or related forms of dementia, according to new research.

Brain scans capture memory formation in babies, raising new questions about why people forget their earliest years ...

AI-personalized brain stimulation improved sustained attention in people with low baseline focus in an exciting new study.

Caregiving is a tough job that affects everyone, regardless of their celebrity or financial status. That's why some big names ...

Lecanemab, approved by the FDA in 2023 to treat early Alzheimer's disease, is a monoclonal antibody that binds with high affinity to amyloid-beta soluble protofibrils. In the phase III CLARITY-AD ...

Dementia, a condition impacting memory and cognitive functions, poses a significant global health challenge. Research ...

Amityville’s new Barbara Rabinowitz Education & Resource Center includes even a special transit-focused room to teach families how to travel with their affected loved ones — using items such ...

While Alzheimer’s is a specific disease and the most common cause of dementia, dementia is a broader, "umbrella term that describes a collection of cognitive, functional and behavioral symptoms ...

In a real-world study, infusion-related reactions occurred in 37% of Alzheimer's patients treated with lecanemab. Amyloid-related imaging abnormalities (ARIA) emerged in 22% of treated patients.